Skip to main content
OpenTrials
Completed

NCT Number: NCT00354003

The Study of the Impact of Disclosing Imaging Study Information to Trial Participants

The overall goal of the study is to evaluate how research participants in Parkinson Disease studies that include brain imaging with a dopamine transporter ligand choose to receive the imaging data and what is the impact of the imaging data information on the management of their symptoms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinsonian Syndrome Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Parkinson Parkinsonian Disorders

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institute for Neurodegenerative Disorders

New Haven, Connecticut, 06510, United States

About this study

Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Previous participation in imaging study as described within the protocol

Exclusion criteria

-

Treatment and study plan

A series of questionnaires

Behavioral

Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.

Sponsors and collaborators

Lead sponsor

Institute for Neurodegenerative Disorders

Other

Registry information

Official study title

Impact of Disclosure of Dopamine Transporter Imaging Studies in PD Clinical Trials

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Jul 19, 2006
Registry last updated
Apr 3, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.